Tsuruha Holdings (3391) Q2 2027 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2027 earnings summary
7 Oct, 2026Executive summary
Reported H1 net sales were ¥1,275,514 million, operating income ¥54,770 million and net income attributable to owners ¥30,252 million, up 128.7%, 92.6% and 48.5% YoY following the WELCIA integration.
On a comparable basis, H1 sales rose 3.0% and operating income 3.2%, while net income fell 16.6%, mainly due to the absence of a prior-year ¥6.6 billion securities-sale gain.
Integration synergies and SG&A control supported margin improvement and operating-income growth; unfavorable weather weighed on Q2 sales.
Financial highlights
Consolidated gross profit was ¥393,589 million, up 4.5% on a comparable basis; SG&A was ¥338,818 million, up 4.8%.
Ordinary income was ¥54,850 million; reported YoY growth was 90.3%, versus 1.1% on a comparable basis.
EBITDA was ¥85,530 million, up 126.3% on a reported basis and 13.4% on a comparable basis.
Net sales reached 99.7% of plan; operating income was 103.2%, ordinary income 105.7% and net income 111.2% of plan.
Basic and diluted EPS were ¥66.75 and ¥66.65, versus ¥83.64 and ¥83.32 in the prior-year period.
Outlook and guidance
FY2/27 guidance remains unchanged: net sales ¥2,555,000 million, EBITDA ¥162,300 million, operating income ¥99,400 million, ordinary income ¥98,100 million and net income ¥41,500 million.
Full-year integration-synergy plan is ¥15.0 billion; H1 progress was ~57%.
H2 priorities include gradual category-level merchandising integration, supplier alignment, private-brand development, priority-product sales and broader TOPVALU food-product use.
Next-year initiatives include assortment and promotion optimization, continued supplier negotiations, joint fixture procurement, and a unified app and points program.
Forecasts are based on available information and remain subject to significant uncertainty as business conditions change.
Latest events from Tsuruha Holdings
- Net sales rose 133.7% and operating income climbed 94.3% year-over-year, driven by integration.3391
Q1 2027 - Medium-term plan targets ¥2.7 trillion sales by FY2/29 with integrated, quality-focused growth.3391
Investor presentation - Net income surpassed plan, fueled by integration gains and strong sales growth.3391
Q4 2026 - Nine-month net sales were ¥833,383 million, with WELCIA integration completed.3391
Q3 2026 - Sales and profits surpassed targets, with strong pharmacy growth, stock split, and integration plans ahead.3391
Q2 2026 - Net sales and operating income surpassed targets amid robust food and pharmacy growth and integration plans.3391
Q1 2026 - Transitional period saw solid sales and profit, with FY2026 guidance projecting further growth.3391
Q4 2025 - Q1 profit and sales rose, outlook steady despite one-time costs from fiscal year change.3391
Q1 2025 - Sales rose 5.9% but net income dipped on impairment; FY2025 outlook is for strong profit growth.3391
Q4 2024